Related Experiment Videos
Donepezil in severe Alzheimer's disease
1Karolinska Institutet, Stockholm, Sweden. bengt.winblad@ki.se
American Journal of Alzheimer'S Disease and Other Dementias
|February 28, 2009
Summary
Donepezil offers functional and cognitive benefits for severe Alzheimer's disease patients, even when care needs are high. This medication is well-tolerated and suitable as a first-line treatment across all stages of Alzheimer's disease.
Area of Science:
- Neurology
- Pharmacology
- Geriatrics
Background:
- Severe Alzheimer's disease (AD) diminishes functional autonomy and increases challenging behavioral symptoms.
- Healthcare professionals often question the efficacy of pharmacologic interventions in advanced AD stages.
- Primary care physicians play a crucial role in managing AD patients and initiating appropriate referrals.
Purpose of the Study:
- To evaluate the benefits of donepezil in patients with severe Alzheimer's disease.
- To assess the safety and tolerability of donepezil in this patient population.
Main Methods:
- Conducted three prospective randomized clinical trials involving patients with severe Alzheimer's disease.
- Assessed functional, cognitive, and behavioral outcomes in patients receiving donepezil.
- Monitored for side effects and overall tolerability.
Main Results:
- Donepezil treatment demonstrated significant functional and cognitive benefits in severe Alzheimer's disease.
- Behavioral benefits were not consistently observed across all trials.
- Donepezil was generally well-tolerated, with transient, mild to moderate cholinergic side effects.
Conclusions:
- Donepezil provides benefits throughout the Alzheimer's disease spectrum.
- It represents a viable first-line monotherapy option for patients in all stages of Alzheimer's disease.
- The drug's favorable safety profile supports its continued use in managing Alzheimer's disease.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...